mk 0663 has been researched along with tolvaptan in 1 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 967 | 172 | 786 |
| Protein | Taxonomy | mk 0663 (IC50) | tolvaptan (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.99 | |
| Vasopressin V2 receptor | Homo sapiens (human) | 0.1486 | |
| Vasopressin V1a receptor | Homo sapiens (human) | 0.351 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for mk 0663 and tolvaptan
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |